Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:17665994rdf:typepubmed:Citationlld:pubmed
pubmed-article:17665994lifeskim:mentionsumls-concept:C0015576lld:lifeskim
pubmed-article:17665994lifeskim:mentionsumls-concept:C0087111lld:lifeskim
pubmed-article:17665994lifeskim:mentionsumls-concept:C0004364lld:lifeskim
pubmed-article:17665994lifeskim:mentionsumls-concept:C0393022lld:lifeskim
pubmed-article:17665994lifeskim:mentionsumls-concept:C0339143lld:lifeskim
pubmed-article:17665994lifeskim:mentionsumls-concept:C1883712lld:lifeskim
pubmed-article:17665994lifeskim:mentionsumls-concept:C0333668lld:lifeskim
pubmed-article:17665994pubmed:issue7lld:pubmed
pubmed-article:17665994pubmed:dateCreated2007-8-1lld:pubmed
pubmed-article:17665994pubmed:abstractTextIn this review, the authors summarise the clinical results obtained after therapy with rituximab in autoimmune diseases, including Graves' disease and Graves' ophthalmopathy. On the basis of qualitative and quantitative analyses of B- and T-cell subsets, and autoantibody levels obtained in other diseases before and after rituximab therapy, the authors interpret the results of the only two clinical investigations of the efficacy of rituximab in the treatment of Graves' disease and Graves' opthalmopathy reported so far. No significant effect on autoantibody levels was observed. Nonetheless, 4 out of 10 Graves' disease patients remained in remission 400 days after rituximab treatment versus none in the control group, and remarkable improvements in the eye symptoms of patients with Graves' ophthalmopathy were observed. This supports a role for B cells in the pathogenesis of Graves' ophthalmopathy, and the authors suggest that abrogation of antigen presentation by B cells accounts for the effect of rituximab. In the authors' opinion, the use of rituximab in severe Graves' ophthalmopathy could be contemplated.lld:pubmed
pubmed-article:17665994pubmed:languageenglld:pubmed
pubmed-article:17665994pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17665994pubmed:citationSubsetIMlld:pubmed
pubmed-article:17665994pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17665994pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17665994pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17665994pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17665994pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17665994pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17665994pubmed:statusMEDLINElld:pubmed
pubmed-article:17665994pubmed:monthJullld:pubmed
pubmed-article:17665994pubmed:issn1744-7682lld:pubmed
pubmed-article:17665994pubmed:authorpubmed-author:HegedüsLaszlo...lld:pubmed
pubmed-article:17665994pubmed:authorpubmed-author:BendtzenKlaus...lld:pubmed
pubmed-article:17665994pubmed:authorpubmed-author:HasselbalchHa...lld:pubmed
pubmed-article:17665994pubmed:authorpubmed-author:NielsenClaus...lld:pubmed
pubmed-article:17665994pubmed:authorpubmed-author:El...lld:pubmed
pubmed-article:17665994pubmed:issnTypeElectroniclld:pubmed
pubmed-article:17665994pubmed:volume7lld:pubmed
pubmed-article:17665994pubmed:ownerNLMlld:pubmed
pubmed-article:17665994pubmed:authorsCompleteYlld:pubmed
pubmed-article:17665994pubmed:pagination1061-78lld:pubmed
pubmed-article:17665994pubmed:dateRevised2010-11-18lld:pubmed
pubmed-article:17665994pubmed:meshHeadingpubmed-meshheading:17665994...lld:pubmed
pubmed-article:17665994pubmed:meshHeadingpubmed-meshheading:17665994...lld:pubmed
pubmed-article:17665994pubmed:meshHeadingpubmed-meshheading:17665994...lld:pubmed
pubmed-article:17665994pubmed:meshHeadingpubmed-meshheading:17665994...lld:pubmed
pubmed-article:17665994pubmed:meshHeadingpubmed-meshheading:17665994...lld:pubmed
pubmed-article:17665994pubmed:meshHeadingpubmed-meshheading:17665994...lld:pubmed
pubmed-article:17665994pubmed:meshHeadingpubmed-meshheading:17665994...lld:pubmed
pubmed-article:17665994pubmed:meshHeadingpubmed-meshheading:17665994...lld:pubmed
pubmed-article:17665994pubmed:meshHeadingpubmed-meshheading:17665994...lld:pubmed
pubmed-article:17665994pubmed:meshHeadingpubmed-meshheading:17665994...lld:pubmed
pubmed-article:17665994pubmed:meshHeadingpubmed-meshheading:17665994...lld:pubmed
pubmed-article:17665994pubmed:meshHeadingpubmed-meshheading:17665994...lld:pubmed
pubmed-article:17665994pubmed:meshHeadingpubmed-meshheading:17665994...lld:pubmed
pubmed-article:17665994pubmed:meshHeadingpubmed-meshheading:17665994...lld:pubmed
pubmed-article:17665994pubmed:year2007lld:pubmed
pubmed-article:17665994pubmed:articleTitleB-cell depletion with rituximab in the treatment of autoimmune diseases. Graves' ophthalmopathy the latest addition to an expanding family.lld:pubmed
pubmed-article:17665994pubmed:affiliationUniversity of Copenhagen, Department of Clinical Immunology and Blood Bank, Herlev Hospital, Herlev, Denmark. Claushnielsen@hotmail.comlld:pubmed
pubmed-article:17665994pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:17665994pubmed:publicationTypeReviewlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:17665994lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:17665994lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:17665994lld:pubmed